Customize your JAMA Network experience by selecting one or more topics from the list below.
Author Affiliations: Moorfields Eye Hospital (Drs Sohn, Patel, MacLaren, Adatia, Pal, Webster, and Tufail) and UCL Institute of Ophthalmology (Drs MacLaren and Webster), London, and Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford (Dr MacLaren), England; and University of Iowa Hospitals and Clinics, Iowa City (Dr Sohn).
Doyne honeycomb retinal dystrophy (DHRD), malattia leventinese, and dominant radial drusen are allelic conditions that typically present with maculopathy of early age and autofluorescent drusen in the posterior pole with late hyperpigmentation and atrophy of the retinal pigment epithelium (RPE).1 These conditions are caused by a single R345W mutation in the gene encoding epidermal growth factor–containing fibrillin-like extracellular matrix protein 1 (EFEMP1),2 also known as fibulin 3. Development of choroidal neovascularization (CNV) is an uncommon but known sight-threatening complication1 for which the only recently reported intervention for this condition—vitrectomy and subretinal membrane removal3—requires complex surgery. Because of phenotypic similarities but pathophysiologic differences to age-related macular degeneration, we sought to determine the effects of intravitreal treatment with bevacizumab in patients with DHRD.
Sohn EH, Patel PJ, MacLaren RE, et al. Responsiveness of Choroidal Neovascular Membranes in Patients With R345W Mutation in Fibulin 3 (Doyne Honeycomb Retinal Dystrophy) to Anti–Vascular Endothelial Growth Factor Therapy. Arch Ophthalmol. 2011;129(12):1626–1628. doi:https://doi.org/10.1001/archophthalmol.2011.338
Create a personal account or sign in to: